Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Schell

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Molecular Systems Biology|November 6, 2013
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsJiannong Li, Keiryn Bennett, Alexey Stukalov, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 2015
Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutationNishi Kothari, Richard Kim, Robert N Jorissen, et al.
Journal of Clinical Trials|February 18, 2014
Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome MeasuresNagi Kumar, Theresa Crocker, Tiffany Smith, et al.
Contemporary Clinical Trials|November 22, 2011
Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancerNagi Kumar, Theresa Crocker, Tiffany Smith, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 10, 2020
Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLCJacob G Scott, Geoff Sedor, Jessica A Scarborough, et al.
American Journal of Clinical Oncology|September 4, 2025
Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical TrialRobin Park, Fahad Rind, Tyler Kristoff, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Molecular Systems Biology|November 6, 2013
Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanismsJiannong Li, Keiryn Bennett, Alexey Stukalov, et al.
Acta Oncologica (Stockholm, Sweden)|January 1, 2015
Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutationNishi Kothari, Richard Kim, Robert N Jorissen, et al.
Journal of Clinical Trials|February 18, 2014
Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome MeasuresNagi Kumar, Theresa Crocker, Tiffany Smith, et al.
Contemporary Clinical Trials|November 22, 2011
Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancerNagi Kumar, Theresa Crocker, Tiffany Smith, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 10, 2020
Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLCJacob G Scott, Geoff Sedor, Jessica A Scarborough, et al.
American Journal of Clinical Oncology|September 4, 2025
Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical TrialRobin Park, Fahad Rind, Tyler Kristoff, et al.
Pageof 3